Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-02-22
2009-11-17
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266200, C514S266300, C514S230500
Reexamination Certificate
active
07618977
ABSTRACT:
Medicaments for the treatment of dermatitis exhibiting a biphasic inflammation reaction or dermatitis induced by repeated exposure to an antigen, having quinazolidone derivatives of formula I or II that are herein defined, are disclosed.
REFERENCES:
patent: 4684654 (1987-08-01), Wright, Jr. et al.
patent: 4854965 (1989-08-01), Bracha et al.
patent: 2336909 (2000-01-01), None
patent: 795548 (1997-09-01), None
patent: 0 936 216 (1999-08-01), None
patent: 218381 (1996-05-01), None
patent: 5-9175 (1993-01-01), None
patent: 5-294930 (1993-11-01), None
patent: 10-87493 (1998-04-01), None
patent: 10-101666 (1998-04-01), None
patent: 10-245384 (1998-09-01), None
patent: 93/03625 (1993-03-01), None
patent: 93/25574 (1993-12-01), None
patent: 94/26722 (1994-11-01), None
patent: 96/04248 (1996-02-01), None
patent: 96/33974 (1996-10-01), None
patent: 96/39373 (1996-12-01), None
patent: 97/11941 (1997-04-01), None
patent: 98/18794 (1998-05-01), None
patent: WO98/09949 (1998-12-01), None
patent: 99/41277 (1999-08-01), None
patent: 00/03997 (2000-01-01), None
patent: 00/10982 (2000-03-01), None
patent: 00/51640 (2000-09-01), None
patent: 01/32214 (2001-05-01), None
patent: 01/62292 (2001-08-01), None
patent: 01/62293 (2001-08-01), None
The Merck Index, 17thedition (1999), pp. 788-789.
Fukami et al., Current Pharmaceutical Design, (4), (1998), 439-453.
Teruaki Imada, “Therapeutic potential of specific chymase inhibitor in atopic dermatitis,” Abstract, Jan. 2000, Journal of Allergy and Clinical Immunology, vol. 105, No. 1, part 2, p. S267.
Hiroichi Nagai, et al, “An Immunopharmacological Study of the Biphasic Allergic Skin Reaction in Mice,” Biol. Pharm. Bull., vol. 18, No. 2, Feb. 1995, pp. 239-245.
Hiroichi Nagai, et al, “FK-506 and Cyclosporin A Potentiate the IgE Antibody Production by Contact Sensitization with Hapten in Mice,” The Journal of Pharmacology and Experimental Therapeutics, 1997, vol. 283, No. 1, pp. 321-327.
Hiroichi Nagai, PhD, et al, “Imunoglobulin E production in mice by means of contact sensitization with a simple chemical, hapten,” J. Allergy Clin. Immunol., vol. 100, No. 6, part 2, Dec. 1997, pp. S39-S44.
Hideki Kitagaki, et al, “Repeated Elicitation of Contact Hypersensitivity Induces a Shift in Cutaneous Cytokine Milieu from a T Helper Cell Type 1 to a T Helper Cell Type 2 Profile,” The Journal of Immunology, vol. 159, No. 5, Sep. 1, 1997, pp. 2484-2491.
Hideki Kitagaki, et al, “Immediate-Type Hypersensitivity Response Followed by a Late Reaction Is Induced by RepeatedEpicutaneous Application of Contact Sensitizing Agents in Mice,” The Journal of Investigative Dermatology, vol. 105, No. 6, Dec. 1995, pp. 749-755.
Masaoki Tsudzuki, et al, “Genetic analyses for dermatitis and IgE hyperproduction in the NC/Nga mouse,” Immunogenetics, vol. 47, 1997, pp. 88-90.
Hiroshi Matsuda, et al, “Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice,” International Immunology, vol. 9, No. 3, Mar. 1997, pp. 461-466.
Monika Welle, “Development, significance, and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase,” Journal of Leukocyte Biology, vol. 61, Mar. 1997, pp. 233-245.
Shaoheng He, et al, “The induction of a prolonged increase in microvascular permeability by human mast cell chymase,” European Journal of Pharmacology, vol. 352, 1998, pp. 91-98.
Shaoheng He, et al, “Human mast cell chymase induces the accumulation of neutrophils, eosinophils and other inflammatory cells in vivo,” British Journal of Pharmacology, vol. 125, 1998, pp. 1491-1500.
Hitoshi Mizutani, et al, “Rapid and Specific Conversion of Precursor Interleukin 1β (IL-1β) to an Active IL-1 Species by Human Mast Cell Chymase,” J. Exp. Med., vol. 174, No. 4, Oct. 1991, pp. 821-825.
B. Jack Longley, et al, “Chymase cleavage of stem cell factor yields a bioactive, soluble product,” Proc. Natl. Acad. Sci., vol. 94, Aug. 1997, pp. 9017-9021.
Marilyn C. Ray, et al, “Contact Hypersensitivity Reactions to Dinitrofluorobenzene mediated by Monoclonal IgE Anti-DNP Antibodies,” The Journal of Immunology, vol. 131, No. 3, Sep. 1983, pp. 1096-1102.
Takahiro Kunisada, et al, “Murine Cutaneous Mastocytosis and Epidermal Melanocytosis Induced by Keratinocyte Expression of Transgenic Stem Cell Factor,” J. Exp. Med., vol. 187, No. 10, May 1998, pp. 1565-1573.
John J. Costa, et al, “Recombinant Human Stem Cell Factor (Kit Ligand) Promotes Human Mast Cell and Melanocyte Hyperplasia and Functional Activation In Vivo,” J. Exp. Med., vol. 183, No. 6, Jun. 1996, pp. 2681-2686.
B. Lack Longley , Jr., M.D., et al, “Altered Metabolism of Mast-Cell Growth Factor (c-kitLigand) in Cutaneous Mastocytosis,” The New England Journal of Medicine, vol. 328, No. 18, May 6, 1993, pp. 1302-1307.
Tercero et al., “N-Arilsulfonil Ditiocarbamatos de Metilo Como Intermedios en la Sintesis de Heterociclos. Preparacion de Los Sistemas Isomeros 2-Arilsulfonilamino-3-1, 4H-Benzoxazin-4-Onas Y S-Arilsulfonyl-2-4 (1H, 3H)-Quinazolindionas,”Anal. Quimica, Ser. C, vol. 83, No. 2, pp. 247-250 (1987) (no translation).
Okunishi et al., “Role of mast cell chymase in excessive wound-healing response to vascular injury,”Japan. J. Inflamm., vol. 14, pp. 193-197 (1994).
Serruys et al., “Does the New Angiotensis Converting Enzyme Inhibitor Cilazapril Prevent Restenosis After Percutaneous Transluminal Coronary Angioplasty?”Circulation, vol. 86, No. 1, pp. 100-110 (1992), Lippincott Williams & Wilkins, Hagerstown, MD.
Urata et al., “Identification of a Highly Specific Chymase As the Major Angiotensis II-Forming Enzyme in the Human Heart,”J. Biol. Chem., vol. 265, pp. 22348-22356 (1990), American Society for Biochemistry and Molecular Biology, Baltimore, MD.
Naftilan et al., “Angiotensis II Induces c-fos Expression in Smooth Muscle Via Transcriptional Control,”Hypertension, vol. 13, pp. 706-711 (1989), American Heart Association, Dallas, Texas.
Okunishi et al., “Different Distribution of Two Types of Angiotensin II-Generating Enzymes in the Aortic Wall,”Biochem. Biophys. Res. Comm., vol. 149, pp. 1186-1192 (1987), Biochemical and Biophysical Research Communications.
Okunishi et al., “Evidence for A Putatively New Angiotensin II-Generating Enzyme in the Vascular Wall,”J. Hypertension, vol. 2, pp. 277-284 (1984), Gower Academic Journals, London, New York.
Fukami Harukazu
Fukuda Yoshiaki
Tomimori Yoshiaki
Watanabe Naohiro
Asubio Pharma Co. Ltd.
Drinker Biddle & Reath LLP
Spivack Phyllis G.
LandOfFree
Method of treating dermatitis comprising administering a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating dermatitis comprising administering a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating dermatitis comprising administering a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4113163